Klotho Neurosciences, Inc.(KLTO)Earnings, Financials & Key Ratios
KLTO•NASDAQ
$0.38
Price updated Jun 20, 2026
AboutKlotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.Show more
- Revenue$0
- EBITDA-$6M-817.8%
- Net Income-$6M-769.4%
- EPS (Diluted)-0.32-45614.3%
- ROE-700.07%-766.3%
KLTO Price & Volume
Klotho Neurosciences, Inc. (KLTO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Burn Masks Clinical Development Risks
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk
Key Thesis Takeaways
- Klotho Neurosciences remains a pre-revenue entity heavily reliant on external capital to sustain its preclinical research pipeline, as evidenced by a $2.9 million net loss in 2025Q3.
- The company's financial trajectory is characterized by extreme volatility in equity and a reliance on non-cash compensation to manage talent, which may indicate significant dilution risks for shareholders.
- Investors should monitor the firm's ability to advance its intellectual property, as the $2.3 million in goodwill on the balance sheet remains vulnerable to impairment if clinical milestones are not met.
Verdict Logic
the company's precarious liquidity position, evidenced by a $2.9 million net loss in 2025Q3 and a history of deep negative retained earnings, suggests substantial risk of further dilutive capital raises.
KLTO Growth Metrics
Klotho Neurosciences, Inc. (KLTO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-168.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-49.77%
Return on Capital
10 Years-213.55%
5 Years-213.55%
3 Years-248.72%
Last Year-621.96%
Peers Comparison
Key metrics vs top competitors for Klotho Neurosciences, Inc. (KLTO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.38 | $7.33M | -1.19 | — | — | -700.07% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $3.95 | $68.19M | -2.94 | — | -1070.26% | — | — | |
| $2.51 | $255.45M | -2.89 | -86.92% | -1971.7% | -101.76% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — |
Compare KLTO vs Peers
Klotho Neurosciences, Inc. (KLTO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when KLTO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KLTO Frequently Asked Questions
Klotho Neurosciences, Inc. (KLTO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is KLTO profitable?
Klotho Neurosciences, Inc. (KLTO) reported a net loss of $11.3M for fiscal year 2024.
Dividend & Returns
What is KLTO's return on equity?
Klotho Neurosciences, Inc. (KLTO) has a return on equity (ROE) of -700.1%. Negative ROE indicates the company is unprofitable.
What is Klotho Neurosciences, Inc.'s free cash flow?
Klotho Neurosciences, Inc. (KLTO) had negative free cash flow of $5.6M in fiscal year 2024, likely due to heavy capital investments.